Citius Oncology Inc (CTOR) Stock Price, Quote & News

Company Profile

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 908 967 6677

Website: citiusonc.com

Address:

11 Commerce Drive, First Floor, Cranford, United States

ekpemofolo Jul. 28 at 6:25 PM

$CTOR Earnings coming up in a couple of weeks. My idea from few months ago haven't changed. Initial stocking and subsequent disappointing quarter are behind us. Without a sales force in place during the quarter, I will rein in my usual optimism and assume no growth in sales at all. Even then, my calculation gives $4.2 m revenue for this quarter. Dumb penny-market will take it as a huge Q-to-Q increase, and there will be fireworks here. That is my view and it is not investment advice.

1 · Reply

Stockinvestor73 Jul. 25 at 2:15 AM

$ADAPY i found the perfexr reverse merger target........ It's $CTOR

0 · Reply

TwongStocks Jul. 21 at 1:28 PM

$CTOR Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption https://citiusonc.com/news/news-details/2026/Citius-Oncology-Reports-Nationwide-Deployment-of-LYMPHIRs-Broadened-Commercial-Organization-and-Expanding-Market-Adoption/default.aspx "Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by August " 8 months after commercial launch, they'll finally have a full commercial & medical affairs team.

1 · Reply

topstockalerts Jul. 21 at 12:54 PM

Pre Market Top Gainers PT2 $VIVS $RPT $POM $LASE $CTOR

0 · Reply

Bren10OD Jul. 20 at 8:57 PM

$CTOR let’s just do the reverse split already

0 · Reply

JackCampbell Jul. 13 at 1:28 PM

$CTXR $CTOR The t-regs therapy will be our wormhole to other galaxies!!

1 · Reply

donein12 Jul. 6 at 10:56 AM

$CTOR There may be news released today, but it appears NOT to be good at this point in time. Just have to wait and see.

1 · Reply

JackCampbell Jul. 1 at 4:54 PM

$CTXR $CTOR for all crying about Lenny here...its really irrelevant. Relevant is that Lymphir is the one and only approved T-reg depleting therapy on the market, delivering unmatched efficacy in its class. By breaking down immune resistance, it serves as a powerful cornerstone for next-generation oncological combination therapies.$MRK $GILD and many other....

4 · Reply

JackCampbell Jun. 17 at 6:05 PM

$CTXR $CTOR buyout anytime by BP because of incredible two phase 1 results (combination therapies lymphir with other oncology drugs/ t-regs)!

1 · Reply

TwongStocks Jun. 11 at 10:18 PM

$CTXR $CTOR New interview with Leonard. Nearly 30 minutes long, but not much new or useful info for investors. https://www.youtube.com/watch?v=QeAmOx6T6cU Mino-Lok: Still waiting for next steps from FDA. Lymphir: Confirmed that they launched in Dec without a sales force. First wave of sales force hirings happened this week.

2 · Reply

Citius Oncology provides update on commercial launch of Lymphir

CTXR

Jul 21, 2026, 9:17 AM EDT - 11 days ago

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

CTXR

2026-06-01T12:16:52.000Z - 2 months ago

Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO

CTXR

$Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies$

Jun 1, 2026, 7:00 AM EDT - 2 months ago

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

CTXR

2026-05-29T20:41:31.000Z - 2 months ago

Citius Oncology registers to sell 32.93M shares of common stock for holders

May 29, 2026, 8:00 AM EDT - 2 months ago

Citius Oncology Registration statement: Registration filing

May 26, 2026, 8:00 AM EDT - 2 months ago

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

CTXR

May 15, 2026, 4:30 PM EDT - 2 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

CTXR

May 15, 2026, 4:30 PM EDT - 2 months ago

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

CTXR

May 15, 2026, 7:00 AM EDT - 2 months ago

Citius Oncology Quarterly report: Q2 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

Citius Oncology Earnings release: Q2 2026

May 5, 2026, 8:00 PM EDT - 3 months ago

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

2026-04-29T14:53:58.000Z - 3 months ago

Citius Oncology announces initial shipment of LYMPHIR to Europe

CTXR

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Citius Oncology Ships First International Order of LYMPHIR™ to Europe

CTXR

2026-03-31T13:40:30.000Z - 4 months ago

Citius Oncology provides commercial update on lymphir launch

Mar 31, 2026, 9:11 AM EDT - 4 months ago

Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development

CTXR

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts

CTXR

2026-03-10T12:58:01.000Z - 5 months ago

Citius Oncology’s Lymphir shows positive results in gynecologic cancers

$Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers$

Mar 10, 2026, 8:47 AM EDT - 5 months ago

Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

CTXR

2026-03-04T14:21:26.000Z - 5 months ago

Citius Oncology reports results from Phase 1 trial evaluating LYMPHIR

Mar 4, 2026, 9:15 AM EST - 5 months ago

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma

CTXR

2026-02-13T13:16:23.000Z - 6 months ago

Citius Oncology reports Q1 EPS (6c) vs. (9c) last year

CTXR

2026-02-13T13:10:44.000Z - 6 months ago

Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year

CTXR

Feb 13, 2026, 8:00 AM EST - 6 months ago

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

CTXR

Feb 13, 2026, 8:00 AM EST - 6 months ago

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

CTXR

Feb 13, 2026, 7:00 AM EST - 6 months ago

Citius Oncology Quarterly report: Q1 2026

Feb 13, 2026, 7:00 AM EST - 6 months ago

Citius Oncology Earnings release: Q1 2026

Feb 11, 2026, 8:00 AM EST - 6 months ago

Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar

CTXR

Jan 5, 2026, 7:00 AM EST - 7 months ago

Citius Oncology Registration statement: Registration filing

2025-12-23T21:40:21.000Z - 7 months ago

Citius Oncology reports FY25 EPS (34c) vs. (31c) last year

Dec 23, 2025, 4:30 PM EST - 7 months ago

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

CTXR

Dec 23, 2025, 4:30 PM EST - 7 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

CTXR

Dec 23, 2025, 7:00 AM EST - 7 months ago

Citius Oncology Annual report: Q4 2025

Dec 23, 2025, 7:00 AM EST - 7 months ago

Citius Oncology Earnings release: Q4 2025

Dec 10, 2025, 4:30 PM EST - 8 months ago

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CTXR

2025-12-09T13:35:42.000Z - 8 months ago

Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering

CTXR

Dec 9, 2025, 8:30 AM EST - 8 months ago

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CTXR

2025-12-04T13:40:29.000Z - 8 months ago

Citius Oncology expands Lymphir distribution to Turkey and Middle East

Dec 4, 2025, 8:37 AM EST - 8 months ago

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

CTXR

2025-12-01T17:10:12.000Z - 8 months ago

Citius Oncology announces U.S. commercial launch of LYMPHIR

Dec 1, 2025, 12:00 PM EST - 8 months ago

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

CTXR

Dec 1, 2025, 7:00 AM EST - 8 months ago

Citius Oncology Slides: Corporate presentation

Nov 25, 2025, 8:00 AM EST - 8 months ago

Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting

CTXR

2025-11-21T13:45:33.000Z - 9 months ago

Citius Oncology to advance launch of Lymphir with Verix AI integration

CTXR

Nov 21, 2025, 8:37 AM EST - 9 months ago

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

CTXR

2025-10-20T12:40:10.000Z - 10 months ago

Citius Oncology announces distribution agreement with McKesson

CTXR MCK

Oct 20, 2025, 8:37 AM EDT - 10 months ago

Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch

Oct 17, 2025, 5:00 PM EDT - 10 months ago

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

CTXR

2025-10-16T12:50:19.000Z - 10 months ago

Citius Oncology signs exclusive commercialization agreement with EVERSANA

CTXR

Oct 16, 2025, 8:47 AM EDT - 10 months ago

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

CTXR

2025-10-07T12:56:18.000Z - 10 months ago

Citius Oncology signs distribution agreement for Lymphir in Southern Europe

Oct 7, 2025, 8:47 AM EDT - 10 months ago

Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe

Sep 26, 2025, 8:00 AM EDT - 11 months ago

Citius Oncology Proxy statement: Proxy filing

2025-09-23T11:55:20.000Z - 11 months ago

Maxim upgrades Citius Oncology to Buy, sees its capital needs being met

Sep 10, 2025, 4:30 PM EDT - 11 months ago

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTXR

Sep 9, 2025, 8:30 AM EDT - 11 months ago

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTXR

Sep 2, 2025, 8:00 AM EDT - 11 months ago

Citius Oncology Registration statement: Registration filing

Aug 22, 2025, 8:47 AM EDT - 1 year ago

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

CTXR

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Citius Oncology Earnings release: Q3 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Citius Oncology Quarterly report: Q3 2025

Jul 17, 2025, 4:30 PM EDT - 1 year ago

Citius Oncology Announces Closing of $9.0 Million Public Offering

CTXR

Jul 16, 2025, 9:15 AM EDT - 1 year ago

Citius Oncology Announces Pricing of $9.0 Million Public Offering

CTXR

Jul 15, 2025, 8:32 AM EDT - 1 year ago

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

CTXR

Jul 14, 2025, 8:00 AM EDT - 1 year ago

Citius Oncology Registration statement: Registration filing

Jul 14, 2025, 8:00 AM EDT - 1 year ago

Citius Oncology Registration statement: Registration filing

Jun 17, 2025, 8:08 AM EDT - 1 year ago

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

CTXR

May 14, 2025, 4:30 PM EDT - 1 year ago

Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 7:00 AM EDT - 1 year ago

Citius Oncology Quarterly report: Q2 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Citius Oncology Earnings release: Q2 2025

May 5, 2025, 8:37 AM EDT - 1 year ago

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CTXR

Feb 14, 2025, 4:30 PM EST - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

CTXR

Feb 14, 2025, 4:30 PM EST - 1 year ago

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Feb 13, 2025, 7:00 AM EST - 1 year ago

Citius Oncology Quarterly report: Q1 2025

Feb 13, 2025, 7:00 AM EST - 1 year ago

Citius Oncology Earnings release: Q1 2025

Feb 6, 2025, 8:55 AM EST - 1 year ago

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

CTXR

Jan 7, 2025, 8:08 AM EST - 1 year ago

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

CTXR

Jan 6, 2025, 7:50 AM EST - 1 year ago

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

CTXR

Dec 27, 2024, 5:00 PM EST - 1 year ago

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

ekpemofolo Jul. 28 at 6:25 PM

1 · Reply

Stockinvestor73 Jul. 25 at 2:15 AM

$ADAPY i found the perfexr reverse merger target........ It's $CTOR

0 · Reply

TwongStocks Jul. 21 at 1:28 PM

1 · Reply

topstockalerts Jul. 21 at 12:54 PM

Pre Market Top Gainers PT2 $VIVS $RPT $POM $LASE $CTOR

0 · Reply

Bren10OD Jul. 20 at 8:57 PM

$CTOR let’s just do the reverse split already

0 · Reply

JackCampbell Jul. 13 at 1:28 PM

$CTXR $CTOR The t-regs therapy will be our wormhole to other galaxies!!

1 · Reply

donein12 Jul. 6 at 10:56 AM

$CTOR There may be news released today, but it appears NOT to be good at this point in time. Just have to wait and see.

1 · Reply

JackCampbell Jul. 1 at 4:54 PM

4 · Reply

JackCampbell Jun. 17 at 6:05 PM

$CTXR $CTOR buyout anytime by BP because of incredible two phase 1 results (combination therapies lymphir with other oncology drugs/ t-regs)!

1 · Reply

TwongStocks Jun. 11 at 10:18 PM

2 · Reply

Merlintrader Jun. 9 at 1:01 PM

$CTOR Citius Oncology (Nasdaq: $CTOR): LYMPHIR Revenue Is Real Now, But the Commercial Launch Still Sits Inside a High-Risk Small-Cap Biotech Setup https://www.merlintrader.com/citius-oncology-june2026-deepdive/

0 · Reply

History101 Jun. 9 at 4:23 AM

$CTOR come to SLS to recoup your losses

0 · Reply

np_stocks Jun. 5 at 1:18 PM

$CTXR good morning world and everyone , except the management team of $CTXR snd $CTOR . This is your daily reminder not to touch this pos. Have a wonderful Friday and don’t invest in this awful junk. Thank you!

0 · Reply

TwongStocks Jun. 4 at 8:54 PM

$CTXR files new 13D to update beneficial ownership in $CTOR . https://www.sec.gov/Archives/edgar/data/1506251/000121390026065310/xslSCHEDULE_13D_X02/primary_doc.xml CTXR still owns 66,049,615 CTOR shares. Beneficial ownership drops from 77.9% to 71% due to recent dilution of CTOR.

0 · Reply

np_stocks Jun. 3 at 3:23 PM

$CTOR $CTXR avoid at all costs. Better having your money sit in a savings account or mutual funds. A lot of people screwed on this stock for many many years……….. to the planet earth and the world avoid this and protect your families from robbery and theft from this dog shit management team. AVOID !!!!!!!!!!!!!!!

0 · Reply

erichartmann Jun. 3 at 2:38 PM

$CTOR $CTXR $MRK@JackCampbell yeah, maybe buyout for .80! 😂. Lenny is a complete crook! Where is ML? He said he had unsolicited interest on several occasions.. Where/when Lenny! Lier!

0 · Reply

GaryGherkins Jun. 3 at 2:16 PM

$CTOR thoroughly confused by the 2 tickers(ctxr/ctor); can someone please help on which has the better potential upside? thx

1 · Reply

JackCampbell Jun. 2 at 1:55 PM

$CTXR $CTOR no doubt $MRK is watching us closely. Lymphir and Keytruda in combination could be the absolute game changer! https://finance.yahoo.com/sectors/healthcare/articles/citius-oncology-highlights-phase-1-110000653.html

1 · Reply

DARKP00L Jun. 1 at 11:08 AM

$CTOR 07:07 on Jun. 01 2026 Citius Oncology Highlighted Phase 1 Clinical Data Presented May 30, 2026, At The American Society Of Clinical Oncology Annual Meeting Evaluating Lymphir (Denileukin Diftitox-cxdl) In Combination With Pembrolizumab In Patients With Recurrent Or Refractory Gynecologic Malignancies #tradeideas

0 · Reply

Noname2022 May. 30 at 6:15 PM

$CRMD $CTOR $CTXR Interesting breadcrumb: a Citius post about funding LYMPHIR commercialization drew engagement from multiple CorMedix/Melinta commercial personnel across Operations, Value & Access, Marketing, KAM, and Compliance. Could be nothing, but it’s more overlap than I’d expect for a niche oncology launch.

2 · Reply

TwongStocks May. 29 at 9:04 PM

$CTOR The Definitive Notice of Stockholder Action by Written Consent was filed this afternoon. Approval of the warrants is effective June 18. https://www.sec.gov/Archives/edgar/data/1851484/000121390026062911/ea0292248-def14c_citius.htm Summary 👇👇

0 · Reply

Merlintrader May. 27 at 12:07 PM

$LPCN Three Biotech Data Presentations to Watch: Precision BioSciences, Lipocine and Citius Oncology $DTIL $LPCN $CTOR https://www.merlintrader.com/biotech-data-presentations-may2026/

1 · Reply

Market Cap	53.35M
Revenue (ttm)	0.00
Net Income (ttm)	-24.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.34

Volume	39,500
Avg Vol	58,828
Day's Range	N/A - N/A
Shares Out	92.98M
Stochastic %K	37%
Beta	3.47
Analysts	Strong Sell
Price Target	$4.00